메뉴 건너뛰기




Volumn 65, Issue 12, 2013, Pages 2024-2031

Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: Study using the spanish registry of adverse events of biological therapies in rheumatic diseases

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

EID: 84889026653     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22096     Document Type: Article
Times cited : (44)

References (50)
  • 1
    • 70350449256 scopus 로고    scopus 로고
    • New advances in the management of juvenile idiopathic arthritis-2: The era of biologicals
    • Beresford MW, Baildam EM,. New advances in the management of juvenile idiopathic arthritis-2: the era of biologicals. Arch Dis Child Educ Pract Ed 2009; 94: 151-6.
    • (2009) Arch Dis Child Educ Pract Ed , vol.94 , pp. 151-156
    • Beresford, M.W.1    Baildam, E.M.2
  • 2
    • 4544363019 scopus 로고    scopus 로고
    • Biological therapies in the spondyloarthritides: The current state
    • Braun J, Sieper J,. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004; 43: 1072-84.
    • (2004) Rheumatology (Oxford) , vol.43 , pp. 1072-1084
    • Braun, J.1    Sieper, J.2
  • 3
    • 2442590862 scopus 로고    scopus 로고
    • New drugs for rheumatoid arthritis
    • Olsen NJ, Stein CM,. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79.
    • (2004) N Engl J Med , vol.350 , pp. 2167-2179
    • Olsen, N.J.1    Stein, C.M.2
  • 4
    • 78649477259 scopus 로고    scopus 로고
    • TNF-α antagonists beyond approved indications: Stories of success and prospects for the future
    • Karampetsou MP, Liossis SN, Sfikakis PP,. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103: 917-28.
    • (2010) QJM , vol.103 , pp. 917-928
    • Karampetsou, M.P.1    Liossis, S.N.2    Sfikakis, P.P.3
  • 5
    • 84862610971 scopus 로고    scopus 로고
    • Infections in patients with rheumatic diseases treated with TNF antagonists
    • Perez-Zafrilla B, Carmona L, Gomez-Reino JJ,. Infections in patients with rheumatic diseases treated with TNF antagonists. Curr Pharm Biotechnol 2012; 13: 1418-25.
    • (2012) Curr Pharm Biotechnol , vol.13 , pp. 1418-1425
    • Perez-Zafrilla, B.1    Carmona, L.2    Gomez-Reino, J.J.3
  • 6
    • 27744499707 scopus 로고    scopus 로고
    • Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors
    • Chakravarty EF, Michaud K, Wolfe F,. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5.
    • (2005) J Rheumatol , vol.32 , pp. 2130-2135
    • Chakravarty, E.F.1    Michaud, K.2    Wolfe, F.3
  • 7
    • 23644447586 scopus 로고    scopus 로고
    • Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction
    • Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A,. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513-8.
    • (2005) Arthritis Rheum , vol.52 , pp. 2513-2518
    • Sfikakis, P.P.1    Iliopoulos, A.2    Elezoglou, A.3    Kittas, C.4    Stratigos, A.5
  • 8
    • 58849160468 scopus 로고    scopus 로고
    • Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
    • Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
    • (2009) Ann Rheum Dis , vol.68 , pp. 209-215
    • Harrison, M.J.1    Dixon, W.G.2    Watson, K.D.3    King, Y.4    Groves, R.5    Hyrich, K.L.6
  • 9
    • 72949116745 scopus 로고    scopus 로고
    • Development of alopecia areata after biological therapy with TNF-α blockers: Description of a case and review of the literature
    • Hernandez MV, Nogues S, Ruiz-Esquide V, Alsina M, Canete JD, Sanmarti R,. Development of alopecia areata after biological therapy with TNF-α blockers: description of a case and review of the literature. Clin Exp Rheumatol 2009; 27: 892-3.
    • (2009) Clin Exp Rheumatol , vol.27 , pp. 892-893
    • Hernandez, M.V.1    Nogues, S.2    Ruiz-Esquide, V.3    Alsina, M.4    Canete, J.D.5    Sanmarti, R.6
  • 11
    • 84865389552 scopus 로고    scopus 로고
    • Morphea associated with the use of adalimumab: A case report and review of the literature
    • Ramirez J, Hernandez MV, Galve J, Canete JD, Sanmarti R,. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol 2012; 22: 602-4.
    • (2012) Mod Rheumatol , vol.22 , pp. 602-604
    • Ramirez, J.1    Hernandez, M.V.2    Galve, J.3    Canete, J.D.4    Sanmarti, R.5
  • 14
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial
    • Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
    • (2004) Arthritis Rheum , vol.50 , pp. 1400-1411
    • Keystone, E.C.1    Kavanaugh, A.F.2    Sharp, J.T.3    Tannenbaum, H.4    Hua, Y.5    Teoh, L.S.6
  • 15
    • 0031660364 scopus 로고    scopus 로고
    • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
    • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
    • (1998) Arthritis Rheum , vol.41 , pp. 1552-1563
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3    Smolen, J.S.4    Davis, D.5    Macfarlane, J.D.6
  • 16
    • 0033611472 scopus 로고    scopus 로고
    • A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
    • Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
    • (1999) N Engl J Med , vol.340 , pp. 253-259
    • Weinblatt, M.E.1    Kremer, J.M.2    Bankhurst, A.D.3    Bulpitt, K.J.4    Fleischmann, R.M.5    Fox, R.I.6
  • 18
    • 70350049105 scopus 로고    scopus 로고
    • Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor α inhibitors
    • Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA,. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor α inhibitors. Scand J Rheumatol 2009; 38: 328-31.
    • (2009) Scand J Rheumatol , vol.38 , pp. 328-331
    • Exarchou, S.A.1    Voulgari, P.V.2    Markatseli, T.E.3    Zioga, A.4    Drosos, A.A.5
  • 20
    • 33846950349 scopus 로고    scopus 로고
    • Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists
    • Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol 2007; 156: 486-91.
    • (2007) Br J Dermatol , vol.156 , pp. 486-491
    • Lee, H.H.1    Song, I.H.2    Friedrich, M.3    Gauliard, A.4    Detert, J.5    Rowert, J.6
  • 21
    • 77957274056 scopus 로고    scopus 로고
    • Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
    • Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Rosello R, Hernandez MV, Gomez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 1751-5.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1751-1755
    • Garcia-Doval, I.1    Perez-Zafrilla, B.2    Descalzo, M.A.3    Rosello, R.4    Hernandez, M.V.5    Gomez-Reino, J.J.6
  • 22
    • 60749125474 scopus 로고    scopus 로고
    • Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents
    • Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009; 301: 737-44.
    • (2009) JAMA , vol.301 , pp. 737-744
    • Strangfeld, A.1    Listing, J.2    Herzer, P.3    Liebhaber, A.4    Rockwitz, K.5    Richter, C.6
  • 23
    • 84872056023 scopus 로고    scopus 로고
    • Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
    • Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-34.
    • (2013) Ann Rheum Dis , vol.72 , pp. 229-234
    • Galloway, J.B.1    Mercer, L.K.2    Moseley, A.3    Dixon, W.G.4    Ustianowski, A.P.5    Helbert, M.6
  • 24
    • 33747008410 scopus 로고    scopus 로고
    • Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
    • British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register.
    • Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
    • (2006) Arthritis Rheum , vol.54 , pp. 2368-2376
    • Dixon, W.G.1    Watson, K.2    Lunt, M.3    Hyrich, K.L.4    Silman, A.J.5
  • 26
    • 84874748525 scopus 로고    scopus 로고
    • Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster
    • Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-95.
    • (2013) JAMA , vol.309 , pp. 887-895
    • Winthrop, K.L.1    Baddley, J.W.2    Chen, L.3    Liu, L.4    Grijalva, C.G.5    Delzell, E.6
  • 27
    • 33846657544 scopus 로고    scopus 로고
    • Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients
    • Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46: 327-34.
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 327-334
    • Salliot, C.1    Gossec, L.2    Ruyssen-Witrand, A.3    Luc, M.4    Duclos, M.5    Guignard, S.6
  • 29
    • 70449486874 scopus 로고    scopus 로고
    • Innate immunity and allergy in the skin
    • Metz M, Maurer M,. Innate immunity and allergy in the skin. Curr Opin Immunol 2009; 21: 687-93.
    • (2009) Curr Opin Immunol , vol.21 , pp. 687-693
    • Metz, M.1    Maurer, M.2
  • 30
    • 37549005087 scopus 로고    scopus 로고
    • Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients
    • Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G,. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.
    • (2008) Am J Clin Dermatol , vol.9 , pp. 1-14
    • Wollina, U.1    Hansel, G.2    Koch, A.3    Schonlebe, J.4    Kostler, E.5    Haroske, G.6
  • 31
    • 78649445740 scopus 로고    scopus 로고
    • Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis
    • Collamer AN, Battafarano DF,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40.
    • (2010) Semin Arthritis Rheum , vol.40 , pp. 233-240
    • Collamer, A.N.1    Battafarano, D.F.2
  • 32
    • 4043107880 scopus 로고    scopus 로고
    • Alopecia areata in a patient using infliximab: New insights into the role of tumor necrosis factor on human hair follicles
    • [letter].
    • Ettefagh L, Nedorost S, Mirmirani P,. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles [letter]. Arch Dermatol 2004; 140: 1012.
    • (2004) Arch Dermatol , vol.140 , pp. 1012
    • Ettefagh, L.1    Nedorost, S.2    Mirmirani, P.3
  • 34
    • 79955003756 scopus 로고    scopus 로고
    • TNF α antagonist-induced lupus-like syndrome: Report and review of the literature with implications for treatment with alternative TNF α antagonists
    • Williams VL, Cohen PR,. TNF α antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF α antagonists. Int J Dermatol 2011; 50: 619-25.
    • (2011) Int J Dermatol , vol.50 , pp. 619-625
    • Williams, V.L.1    Cohen, P.R.2
  • 39
    • 77956026744 scopus 로고    scopus 로고
    • EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
    • Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010; 69: 1596-602.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1596-1602
    • Dixon, W.G.1    Carmona, L.2    Finckh, A.3    Hetland, M.L.4    Kvien, T.K.5    Landewe, R.6
  • 40
    • 34848893989 scopus 로고    scopus 로고
    • Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
    • Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
    • (2007) Arthritis Rheum , vol.56 , pp. 2886-2895
    • Wolfe, F.1    Michaud, K.2
  • 41
    • 27744527575 scopus 로고    scopus 로고
    • Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
    • Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1421-1426
    • Askling, J.1    Fored, C.M.2    Brandt, L.3    Baecklund, E.4    Bertilsson, L.5    Feltelius, N.6
  • 42
    • 80053565309 scopus 로고    scopus 로고
    • Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis
    • Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1895-1904
    • Mariette, X.1    Matucci-Cerinic, M.2    Pavelka, K.3    Taylor, P.4    Van Vollenhoven, R.5    Heatley, R.6
  • 43
    • 84868470243 scopus 로고    scopus 로고
    • Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors
    • Mariette X, Reynolds AV, Emery P,. Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. Ann Rheum Dis 2012; 71: e2.
    • (2012) Ann Rheum Dis , vol.71
    • Mariette, X.1    Reynolds, A.V.2    Emery, P.3
  • 44
    • 0032930490 scopus 로고    scopus 로고
    • Risk factors of non-melanoma skin cancer in United States veterans patients: A pilot study and review of literature
    • Chuang TY, Brashear R,. Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature. J Eur Acad Dermatol Venereol 1999; 12: 126-32.
    • (1999) J Eur Acad Dermatol Venereol , vol.12 , pp. 126-132
    • Chuang, T.Y.1    Brashear, R.2
  • 45
    • 33750317924 scopus 로고    scopus 로고
    • Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions
    • Douglas KM, Ladoyanni E, Treharne GJ, Hale ED, Erb N, Kitas GD,. Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis 2006; 65: 1341-5.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1341-1345
    • Douglas, K.M.1    Ladoyanni, E.2    Treharne, G.J.3    Hale, E.D.4    Erb, N.5    Kitas, G.D.6
  • 46
    • 84860915531 scopus 로고    scopus 로고
    • The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register
    • Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012; 71: 869-74.
    • (2012) Ann Rheum Dis , vol.71 , pp. 869-874
    • Mercer, L.K.1    Green, A.C.2    Galloway, J.B.3    Davies, R.4    Lunt, M.5    Dixon, W.G.6
  • 48
    • 40349092811 scopus 로고    scopus 로고
    • The epidemiology of glucocorticoid-associated adverse events
    • McDonough AK, Curtis JR, Saag KG,. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20: 131-7.
    • (2008) Curr Opin Rheumatol , vol.20 , pp. 131-137
    • McDonough, A.K.1    Curtis, J.R.2    Saag, K.G.3
  • 49
    • 0033053835 scopus 로고    scopus 로고
    • Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
    • and the European Leflunomide Study Group
    • Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al, and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
    • (1999) Lancet , vol.353 , pp. 259-266
    • Smolen, J.S.1    Kalden, J.R.2    Scott, D.L.3    Rozman, B.4    Kvien, T.K.5    Larsen, A.6
  • 50
    • 23444461026 scopus 로고    scopus 로고
    • Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis
    • Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 2005; 32: 1620-31.
    • (2005) J Rheumatol , vol.32 , pp. 1620-1631
    • Kalden, J.R.1    Antoni, C.2    Alvaro-Gracia, J.M.3    Combe, B.4    Emery, P.5    Kremer, J.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.